Fig. 5.

Validations results in the Rizvi cohort with 34 NSCLC patients. All patients received whole-exome sequencing (WES), TMS18 and TMB by MSK-IMPACT were calculated based on the gene panels using the WES data, accordingly. a–c Survival analyses of progression-free survival (PFS) with TMS18, TMB by IMPACT and TMB by WES based on previous grouping criteria. Higher TMS18 indicated significantly longer PFS in NSCLC (a), whereas there was no significant association between higher TMB by IMPACT or WES method and longer PFS (b–c). d–f Survival analyses of PFS with TMS18, TMB by IMPACT and TMB by WES divided into two groups as indicated. TMS18 outperformed TMB by IMPACT with lower P value while TMB by WES demonstrated the highest efficiency in predict PFS. g–i Number of patients with different clinical responses in High, Moderate and Low groups of TMS18, TMB by WES and TMB by IMPACT